Kyoto University
$750,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Japan
- Fiscal year
- 2021-2022
- Agreement period
- April 1, 2021 – March 31, 2026
- Reference
- nrc-cnrc:172-2021-2022-Q1-991892
Published purpose
Exploiting genome editing technology to engineer enhanced and novel therapeutic attributes into clinically relevant cell types represents a disruptive modality to circumvent current challenges in cell- and gene-based therapies. The goal of this Project is to establish genome engineering tools amenable to automated and high throughput platforms that facilitate the engineering of therapeutic attributes into human induced pluripotent stem cells (iPSCs). Once established, these tools will be foundational to accelerating the innovation and discovery cycles of engineered cell-based therapies with increased safety, affordability and accessibility in the space of regenerative medicine and immunotherapy.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.